Cargando…

Fundamental and Advanced Therapies, Vaccine Development against SARS-CoV-2

Coronavirus disease (COVID-19) caused by the SARS-CoV-2 virus has been affecting the world since the end of 2019. The severity of the disease can range from an asymptomatic or mild course to acute respiratory distress syndrome (ARDS) with respiratory failure, which may lead to death. Since the outbr...

Descripción completa

Detalles Bibliográficos
Autores principales: Hudakova, Nikola, Hricikova, Simona, Kulkarni, Amod, Bhide, Mangesh, Kontsekova, Eva, Cizkova, Dasa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8224379/
https://www.ncbi.nlm.nih.gov/pubmed/34064300
http://dx.doi.org/10.3390/pathogens10060636
_version_ 1783711877452267520
author Hudakova, Nikola
Hricikova, Simona
Kulkarni, Amod
Bhide, Mangesh
Kontsekova, Eva
Cizkova, Dasa
author_facet Hudakova, Nikola
Hricikova, Simona
Kulkarni, Amod
Bhide, Mangesh
Kontsekova, Eva
Cizkova, Dasa
author_sort Hudakova, Nikola
collection PubMed
description Coronavirus disease (COVID-19) caused by the SARS-CoV-2 virus has been affecting the world since the end of 2019. The severity of the disease can range from an asymptomatic or mild course to acute respiratory distress syndrome (ARDS) with respiratory failure, which may lead to death. Since the outbreak of the pandemic, scientists around the world have been studying the genome and molecular mechanisms of SARS-CoV-2 infection to develop effective therapies and prevention. In this review, we summarize the progressive development of various treatments and vaccines as they have emerged, a year after the outbreak of the pandemic. Initially for COVID-19, patients were recommended drugs with presumed antiviral, anti-inflammatory, and antimicrobial effects that were previously used to treat other diseases. Thereafter, therapeutic interventions were supplemented with promising approaches based on antibodies, peptides, and stem cells. However, licensed COVID-19 vaccines remain the most effective weapon in combating the pandemic. While there is an enormous effort to enhance the vaccination rate to increase the entire population immunity, the production and delivery of vaccines is becoming limited in several countries. In this regard, there are new challenges needing to be addressed by combining non-pharmacological intervention with effective therapies until vaccination is accessible to all.
format Online
Article
Text
id pubmed-8224379
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-82243792021-06-25 Fundamental and Advanced Therapies, Vaccine Development against SARS-CoV-2 Hudakova, Nikola Hricikova, Simona Kulkarni, Amod Bhide, Mangesh Kontsekova, Eva Cizkova, Dasa Pathogens Review Coronavirus disease (COVID-19) caused by the SARS-CoV-2 virus has been affecting the world since the end of 2019. The severity of the disease can range from an asymptomatic or mild course to acute respiratory distress syndrome (ARDS) with respiratory failure, which may lead to death. Since the outbreak of the pandemic, scientists around the world have been studying the genome and molecular mechanisms of SARS-CoV-2 infection to develop effective therapies and prevention. In this review, we summarize the progressive development of various treatments and vaccines as they have emerged, a year after the outbreak of the pandemic. Initially for COVID-19, patients were recommended drugs with presumed antiviral, anti-inflammatory, and antimicrobial effects that were previously used to treat other diseases. Thereafter, therapeutic interventions were supplemented with promising approaches based on antibodies, peptides, and stem cells. However, licensed COVID-19 vaccines remain the most effective weapon in combating the pandemic. While there is an enormous effort to enhance the vaccination rate to increase the entire population immunity, the production and delivery of vaccines is becoming limited in several countries. In this regard, there are new challenges needing to be addressed by combining non-pharmacological intervention with effective therapies until vaccination is accessible to all. MDPI 2021-05-21 /pmc/articles/PMC8224379/ /pubmed/34064300 http://dx.doi.org/10.3390/pathogens10060636 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Hudakova, Nikola
Hricikova, Simona
Kulkarni, Amod
Bhide, Mangesh
Kontsekova, Eva
Cizkova, Dasa
Fundamental and Advanced Therapies, Vaccine Development against SARS-CoV-2
title Fundamental and Advanced Therapies, Vaccine Development against SARS-CoV-2
title_full Fundamental and Advanced Therapies, Vaccine Development against SARS-CoV-2
title_fullStr Fundamental and Advanced Therapies, Vaccine Development against SARS-CoV-2
title_full_unstemmed Fundamental and Advanced Therapies, Vaccine Development against SARS-CoV-2
title_short Fundamental and Advanced Therapies, Vaccine Development against SARS-CoV-2
title_sort fundamental and advanced therapies, vaccine development against sars-cov-2
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8224379/
https://www.ncbi.nlm.nih.gov/pubmed/34064300
http://dx.doi.org/10.3390/pathogens10060636
work_keys_str_mv AT hudakovanikola fundamentalandadvancedtherapiesvaccinedevelopmentagainstsarscov2
AT hricikovasimona fundamentalandadvancedtherapiesvaccinedevelopmentagainstsarscov2
AT kulkarniamod fundamentalandadvancedtherapiesvaccinedevelopmentagainstsarscov2
AT bhidemangesh fundamentalandadvancedtherapiesvaccinedevelopmentagainstsarscov2
AT kontsekovaeva fundamentalandadvancedtherapiesvaccinedevelopmentagainstsarscov2
AT cizkovadasa fundamentalandadvancedtherapiesvaccinedevelopmentagainstsarscov2